Oragenics ( NYSE: OGEN ) on Thursday said that it had completed the development of its prototype of its automated intranasal device that would help in treating concussed patients. The company added that a phase II study is being designed to analyze the effectiveness of ONP-002 on blood biomarkers and patient-reported outcomes of concussed patients. The breath-propelled device requires the patient to administer the drug into the nose.
Press release. More on Oragenics Oragenics prices public offering of common stock Oragenics climbs 9% amid Phase 2 study, business updates Financial information for Oragenics.